Physician profile
Peter Dc Ly
NPI 1386881951
$12,945.65
in general payments reported to CMS, 2019-2025
36 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $1,570 · 2021: $3,275 · 2022: $2,226 · 2023: $1,661 · 2024: $1,666 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,762 · Education: $54.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,762.48 |
| Education | $54.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,274.54 | 2019-2024 | Abilify Mycite, Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,327.36 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,091.06 | 2021-2025 | |
| Neos Therapeutics, Lp | $982.14 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Supernus Pharmaceuticals, INC. | $736.38 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $642.56 | 2021-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $613.37 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $609.40 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $473.25 | 2019-2022 | |
| Allergan, INC. | $457.05 | 2019-2020 | |
| Tris Pharma INC | $447.35 | 2023-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $385.37 | 2019-2024 | Jornay Pm |
| Alkermes, INC. | $368.91 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $348.51 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $344.02 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $329.46 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $237.06 | 2024-2025 | Cobenfy |
| Eisai INC. | $221.37 | 2020-2022 | |
| Adlon Therapeutics L.P. | $184.96 | 2019-2021 | |
| Lundbeck LLC | $127.92 | 2020-2023 | Rexulti |
| Gilead Sciences, INC. | $110.68 | 2022 | |
| Bausch Health US, LLC | $93.02 | 2019-2025 | Wellbutrin, Aplenzin |
| Jazz Pharmaceuticals INC. | $92.53 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $76.54 | 2022-2023 | Altreno, Arazlo, Duobrii |
| Vanda Pharmaceuticals INC. | $61.83 | 2024 | Fanapt |
| Noven Therapeutics, LLC | $59.86 | 2021-2025 | Secuado, Xelstrym |
| Vertical Pharmaceuticals, LLC | $58.19 | 2019 | |
| Merck Sharp & Dohme LLC | $45.77 | 2020 | |
| Neuronetics, INC. | $24.98 | 2020 | |
| Mission Pharmacal Company | $22.86 | 2020 | |
| Almatica Pharma LLC | $22.68 | 2021 | |
| Shire North American Group INC | $22.65 | 2019 | |
| Arbor Pharmaceuticals, INC. | $22.02 | 2019-2020 | |
| Alfasigma USA, INC. | $16.17 | 2022 | |
| Galderma Laboratories, L.P. | $13.83 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.